Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. How...

全面介紹

書目詳細資料

發表在:	Pharmaceuticals
Main Authors:	Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili, Carmela Fimognari
格式:	Article
語言:	英语
出版:	MDPI AG 2021-07-01
主題:	coronavirus disease (COVID)-19 janus kinase (JAK) inhibitors baricitinib ruxolitinib real word evidence adverse effects
在線閱讀:	https://www.mdpi.com/1424-8247/14/8/738